This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Bintrafusp alfa for advanced, unresectable cervical cancer

< Back

Bintrafusp alfa for advanced, unresectable cervical cancer


Cancer and Palliative Care

June 2021

Bintrafusp alfa is in clinical development for the treatment of advanced, unresectable, or metastatic cervical cancer. Cervical cancer can be defined as advanced or metastatic when originates in the cervix and spreads to various other parts of the body. If cervical cancer is recurrent, metastatic or persistent, there are limited treatment options, with treatments usually aiming to alleviate symptoms and improve quality of life.
Bintrafusp alfa is a type of protein called an antibody, which can bind to a cancer-causing protein. Therefore, it activates the natural killer (NK) cell to attack the cancer cells. Bintrafusp alfa is administered by intravenous infusion (injection into the vein). If licensed, bintrafusp alfa would offer an additional treatment option for patients with advanced, unresectable and/or metastatic cervical cancer.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article


Connect to the Innovation Observatory


Load More Related Posts

Get Alerts